Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells Rachel E. NicolettoClyde M. Ofner III Review Article 12 February 2022 Pages: 285 - 311
Roles of DNA polymerase ζ in the radiotherapy sensitivity and oxidative stress of lung cancer cells Xialin ChenRong JiMing Chen Original Article 23 January 2022 Pages: 313 - 321
Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer Zhiqiang TongMengfei ChengMei Dong Original Article 24 January 2022 Pages: 323 - 330
Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy Fuyan XuHuizhi XiYong Xia Original Article 24 January 2022 Pages: 331 - 346
Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies Danesh HassaniMahmood Jeddi-TehraniFazel Shokri Original Article 26 January 2022 Pages: 347 - 361
Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors Francois MercierNassim DjebliGeorgina Meneses-Lorente Original Article 03 February 2022 Pages: 363 - 372
Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies Xuyang SongAnis A. KhanMegan Gibbs Original Article 08 February 2022 Pages: 373 - 382
Prediction of drug–drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling Ming ChangSai BathenaAmit Roy Original Article Open access 11 February 2022 Pages: 383 - 392
Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients Ravi RamalingamHarpreet KaurSolomon F. D. Paul Original Article 14 February 2022 Pages: 393 - 400
Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk Weifeng WanWenfeng XiaoJianguo Xu Original Article 16 February 2022 Pages: 401 - 411
Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers Jingquan JiaLauren HowardAndrew B. Nixon Original Article 16 February 2022 Pages: 413 - 422
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies Susana M. CamposSuzanne BerlinRichard T. Penson Clinical Trial Report 10 February 2022 Pages: 423 - 430